Chopin’s Etude in CMV Major
28 June, 2024 10:00 a.m. to 11:00 a.m. EDT
CMV remains a significant challenge in solid organ transplant recipients, with impact on allograft function and toxicities related to treatment. The past several years has been notable for new approaches for prophylaxis and treatment, and greater understanding of the antigen-specific immune response. New antiviral medications (including letermovir and maribavir) and immune monitoring developments have the potential to transform the field. This session will allow for discussion of new approaches to prevention, prophylaxis, treatment, and patient risk stratification.
Moderators
Maheen Abidi, MD, FIDSA, FAST
Bradley Gardiner, MBBS, FRACP, PhD
Presentations
New CMV drugs: Letermovir and Maribavir
Presented by Jennifer Chow, MD
CMV and Telomere Disease
Presented by Marie Budev DO, MPH FCCP
CMV-Cell Mediated Immunity
Presented by Oriol Manuel, MD
